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ABSTRACT. The addition of 2-bromobenzylmagnesium bromide to chiral N-tert-butanesulfinyl 
imines derived from tetralone type ketones proceeds with high levels of diastereocontrol. The 
resulting sulfinamide derivatives were transformed into dibenzoazaspiro compounds after a 
palladium catalyzed intramolecular N-arylation. DFT calculations have been performed to 
rationalize the stereochemical course of the reaction. Similar results have been obtained considering 
either diethyl ether or toluene as a solvent, in both cases in an excellent agreement with 
experimental findings. NCI topological calculations have also been used to evidence crucial non-
covalent interactions. In addition, the azaspiro compounds reduced the viability chronic myeloid 
leukemia cells in the micromolar range. Notably, both the halogen-substituted (R)- and (S)-8g and 
8h as well as (R)-8j were at least two times more effective on a multidrug-resistant derivative than 
on the parental cell line, exerting a collateral sensitivity effect. 
 
KEYWORDS. Chiral sulfinyl imines, tetralones, chromanone, thiochromanone, diastereoselective 
addition, N-arylation, 1-azaspiro[4.5]decanes, DFT calculations, multifactorial drug resistance, 
collateral sensitivity 
 
INTRODUCTION 
The 1-azaspiro[4.5]decane unit (I) is an important structural motif found in natural products and 
also in different synthetic molecules which display interesting pharmacological activities (Figure 1). 
Among the natural products, himandrine (II)1 is an alkaloid isolated from the bark of Galbulimima 
belgraveana and Galbulimima baccata aromatic evergreen trees that grow in Papua New Guinea. 
These trees have been used as medicinal herbs by native tribes to induce sleep or relieve abdominal 
pains.2 The azaspiro unit I was also found in marine alkaloids lepadiformine A (III) which was 
isolated from the tunicate Clavelina lepadiformis3 (Figure 1). Interestingly, lepadiformine A (III) 
exhibits strong cardiovascular effects as well as moderate cytotoxicity.4 Aspidofractinine (IV) and 
3-demethoxyerythratidinone (V) were anothers examples of these natural products which were 
isolated respectively from the leaves of Aspidosperma refractum,5 and  from Erythrina lithosperma 6 
as well as the leading compound of a large family of biological active alkaloids sharing the same 
basic hydrocarbon backbone (Figure 1). On the other hand, compounds with a benzo-1-
azaspiro[4.5]decane unit, such as VI (Figure 1), were found to be inhibitors of kinesin spindle 
protein (KSP), a protein involved in mitosis, and potential therapeutic agents for treating cellular 
proliferative diseases associated with KSP.7   In addition, there are several examples in literature of 
other type of azaspiro compounds which exhibit a wide range of biological activities, including 
anti-leishmanial,8 antibacterial,9 anti-convulsivant,10 analgesic,11 chronic neurologic disorders 
regulator12 and anticancer13 activities.  
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 Figure 1. Representative natural products bearing the 1-azaspiro[4.5]decane unit 
 
  
Being aware of the potential interest of dibenzo 1-azaspiro[4.5]decane derivatives with regard to 
antimitotic effect targeting the cytoskeleton, our interest in the study of the nucleophilic additions to 
N-tert-butanesulfinyl imines, and the influence of the stereogenic center on the stereochemical 
outcome of these reactions, we herein report our approach to the synthesis of these compounds 
through a successive addition of an organomagnesium compound to the corresponding chiral tert-
butanesulfinyl imine and final intramolecular N-arylation (Scheme 1). Since the addition of 
Grignard reagents to these chiral imines proceeds in a diastereoselective manner, the two possible 
enantiomers are accessible by starting from the corresponding (RS)- or (SS)-sulfinyl imine. It is 
worth mentioning that chiral N-tert-butanesulfinyl imines14 have attracted great attention for their 
potential uses in the stereoselective synthesis of amine derivatives containing a stereogenic center 
bonded to the nitrogen atom. For example, Chuang and co-works employed sulfinyl imine and 
organolithium in the synthesis of 3-demethoxyerythratidinone (4) (Figure 1)15. With regards to this, 
we have studied the stereoselective addition to these imines of different reagents, such as allyl16 and 
propargyl17 indium bromides in the presence of indium metal, nitrocompounds,18 enolates19 and 
Grignard reagents.20  
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 Scheme 1. Retrosynthetic analysis of synthesis of dibenzo 1-azaspiro[4.5]decane derivatives 
 
 
RESULTS AND DISCUSSION 
Synthetic studies 
The synthesis of the target dibenzo 1-azaspiro[4.5]decanes started with the diastereoselective 
addition of 2-bromobenzylmagnesium bromide (5) to the corresponding chiral N-tert-butanesulfinyl 
imine (4). Chiral imines 4 were easily accessible by condensation of enantiomerically pure tert-
butanesulfinamide 1, and the corresponding tetralone (2a-h; X = CH2 or CHMe; R = H, MeO, F, 
Br), chromanone (2i; X = O; R = H), or thiochromanone (2j; X = S; R = H) derivative in the 
presence of titanium tetraethoxide. The addition of Grignard reagents to N-tert-butanesulfinyl 
imines was studied for the first time by Ellman and co-workers and showed a remarkable 
dependence of diastereoselectivity using coordinating or non coordinating solvents, the best results 
being obtained in non coordinating solvents.21 It was found that the attack of the Grignard reagent 
occurred on the Si-face of the imine with the R configuration at the sulfur atom. In previous studies, 
we observed that the highest diastereoselectivities in the addition of organomagnesium compounds 
to N-tert-butanesulfinyl imines were obtained in toluene and the lowest diastereoselectivities were 
reached in THF as solvent.20 Based on that, we studied the reaction of a 1 M solution of 2-
bromobenzylmagnesium bromide (5) in ether to the corresponding imine 4 in toluene (Table 1). The 
addition was carried out at -78 ºC, and after that the reaction was allowed to reach room 
temperature. Organomagnesium compound 5 was prepared from 2-bromobenzyl bromide (3) and 
magnesium powder, and in all cases, complete conversion was observed using three equivalents of 
the Grignard reagent 5. The expected sulfinyl amine derivatives 6 were obtained in general in 
moderate yields. The highest yield was found for (RS)-6i (92%), resulting from the addition of 5 to 
the imine 4i derived from chromanone (2i) and (R)-tert-butanesulfinamide [(R)-1]. On the other 
hand, the imine 4a was the model substrate that we took to study these transformations, and yield 
shown on Table 1 for compound (RS)-6a corresponds to the highest yield we obtained after several 
reactions. The reaction conditions were not optimized for the rest of imines 4, neither the reactions 
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were repeated several times. It merits to be mentioned that high yields were also obtained for 
tetralone derivatives 6a (80 and 70% for both enantiomers, Table 1). On the contrary, the lowest 
yields were attained for tetralone derivatives bearing a methoxy group at C6-position of the 
tetralone moiety, due probably to electronic effects (compounds 6d and 6f, Table 1). Unfortunately, 
compound (RS)-6b, derived from 4-methyltetralone (2b), was obtained as a 1:1 mixture of epimers 
which differ in the configuration at C4-position of the tetralone moiety. All these reactions 
proceeded with high diastereoselectivities, and the diastereomeric ratios were easily determined by 
1H-NMR analysis of the crude reaction mixtures, with values over 90:10. In addition, the major 
diastereoisomer was isolated in all cases as a single compound after column chromatography 
purification. Concerning the configuration of the newly created stereogenic centre in compounds 6, 
it was assigned after crystal X-ray analysis (see the Supporting Information) of the solid compound 
(RS)-6h.22 We assume that the nucleophilic attack took always place to the Si-face of the imines 4 
with RS configuration, and to the Re-face of the imines 4 with SS configuration in compounds 6 
(Table 1). 
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Table 1. Diastereoslective addition of 2-bromobenzylmagnesium bromide (5) to chiral imines 4a,b 
           
a Reactions were carried out starting from 1.0 mmol of the corresponding imine 4 in 5 mL of toluene. b Isolated yields 
after column chromatography purification. Diastereomeric ratios are given in parenthesis and were determined from 
1H-NMR spectrum of the crude reaction mixture.
 
Finally, target spiro compounds 8 were obtained from benzyl amine derivatives 6 through a 
sequential removal of the tert-butanesulfinyl group under acidic conditions, and subsequent 
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intramolecular N-arylation of the resulting free amine 7 under palladium catalysis, using Cs2CO3 as 
a base in toluene, in a high pressure tube at 110 ºC for 20 hours (Table 2). Spiro compounds 8 were 
isolated in an enantiomerically pure form in yields ranging from 50% to 70% in most of the cases.  
Table 2. Synthesis of spiro compounds 8 through a sequential desulfinylation and intramolecular N-
arylationa,b 
 
 
 
 
 
a Reactions were carried out starting from 0.5 mmol of the corresponding compound 6. b Isolated yields after column 
chromatography purification. 
 
Theoretical studies 
We performed density-functional theory (DFT) calculations in order to understand the origins of the 
stereocontrol of the reaction between imines 4 and 2-bromobenzylmagnesium bromide (5). The 
nucleophilic addition reaction was studied at b3lyp-d3bj/def2svp level of theory to calculate 
geometries and then single point calculations at b3lyp-d3bj/def2tzvp/pcm=diethylether level of 
theory were performed for obtaining more accurate energy values; calculations in toluene were also 
performed for the purpose of comparison (for details see SI). Since the reaction was performed in a 
mixture of toluene-diethyl ether discrete molecules of dimethyl ether were added to complete the 
tetrahedral coordination sphere of magnesium when necessary. It has been reported that four-
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membered rings formed through a Schlenk equilibrium control Grignard reactions,23 but the 
presence of coordinating solvent molecules can displace the equilibrium towards the free Grignard 
reagent.24 We have studied as a model reaction, the nucleophilic addition of Grignard reagent 5 to 
imine 4a (R = H, X =CH2) as illustrated in Scheme 2).  
 
Scheme 2. General mechanism for the reaction between 4a and 5 
 
Admittedly, nucleophilic additions of organometallic reagents, like Grignard reagents, to 
unsaturated systems capable of complexing the metal atom usually start with the formation of an 
initial complex. Typical examples are Grignard additions to carbonyl compounds25 and nitrones.26 
In the particular case of sulfinyl imines, the sulphoxide group can displace a solvent molecule and 
form the initial complex CP as reported by Eisenstein and co-workers.27 Although the (E)-imine is 
more stable than the (Z)-imine (by 5.1 kcal/mol), there is a rapid equilibrium between both isomers 
of sulfinyl imines27 so, in agreement to Curtin-Hammett’s principle,28 the participation of the (Z)-
isomer cannot be discarded a priori. In consequence, to locate possible transition structures TS we 
defined approaches for (E)- and (Z)-imines by Re and Si faces in which two possible orientations of 
the aryl Grignard reagents are possible due to the presence of the bromine atom, thus being a total 
of eight approaches leading to the two different diastereoisomers that can be obtained (Figure 2).29 
In the final products PRa,b, the magnesium atom is coordinated to both oxygen and nitrogen atoms 
of the sulfinyl amino group in agreement with previous studies.27 
The analysis of the eight located transition structures TSa-h revealed that TSa, corresponding to the 
Grignard addition by the Si face of (E)-isomer and TSg, corresponding to the Grignard addition by 
the Re face of (Z)-isomer, present the lowest barriers with values of 14.3 and 15.4 kcal/mol, 
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respectively (for the complete energy profiles see SI). A Boltzmann distribution corroborated that 
TSa and TSg are essentially the only representative transition structures, with a very minor 
contribution of TSh (see SI). This analysis, obtained considering diethyl ether as a solvent, predict 
an 80:20 diastereomeric ratio for the products. Similar results were observed when toluene was 
considered as a solvent (13.8 and 15.0 kcal/mol for TSa and TSg, respectively), the corresponding 
Boltzmann distribution predicting a diastereomeric ratio of 83:17. These results are in a very good 
agreement with the experimentally observed 90:10 diastereomeric ratio. 
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N
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O
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N
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O
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BrBr Br
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N
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PRa PRb  
Figure 2. Approaches considered for the reaction between 4a and 5. Discrete solvent molecule (s = 
Me2O) coordinated to Mg in TSa-h has been omitted for clarity. TSa-d and TSe-h correspond to 
attacks of 5 by Si and Re faces of 4, respectively.  TSa,b,e,f and TSc,d,g,h correspond to (E) and 
(Z)-imines, respectively. Couples TSa/b, TSc/d, TSe/f and TSg/h correspond to the different 
orientations (bromine atom inside/outside) of the aromatic residue of 5. 
 
The analysis of the optimized geometries of the transition structures revealed interesting features 
that justify the observed differences in energies. For the geometrical analysis we have only 
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considered the most stable transition structure for each attack i.e: TSa and TSc for Si attacks to (E)- 
and (Z)-isomers, respectively, and TSe and TSg for Re attacks to (E)- and (Z)-isomers, respectively 
(Figure 3). The transition structure TSa (Si-attack to (E)-isomer) corresponding to the lowest 
barrier, presents important London interactions between the two aromatic rings without remarkable 
steric requirements. On the other hand, TSe, corresponding to the attack by the other face of the 
same isomer is 9.1 kcal/mol higher in energy, despite the presence of CH-π and halogen-π 
interactions. The reason of such a difference is a steric clash between the entering benzyl group and 
the tert-butyl group, which causes a severe steric hindrance. A similar situation but from a different 
scenario is found for the (Z)-isomer. The transition structure TSg, corresponding to the Re-attack 
and only 1.2 kcal/mol higher in energy than TSa, is the one that presents fewer favorable non-
covalent interactions but it has practically no steric hindrance in the approach of the benzyl group to 
the imine carbon. On the contrary, TSc, showing the highest barrier and corresponding to the attack 
by the Si face, should modify the attack angle because of the presence of the fused cyclohexane 
that, though might give rise to CH-π interactions, it also causes steric difficulties for the attack. 
 
 
Figure 3. Preferred transition structures for each attack. TSa corresponds to the Si attack to (E)-
isomer; TSc corresponds to the Si attack to (Z)-isomer; TSe corresponds to the Re attack to (E)-
isomer and TSg corresponds to the Re attack to (Z)-isomer. 
 
The above mentioned non-covalent interaction are evidenced by means of a topological NCI 
analysis30 in which weak attractive non-covalent interactions are showed as green surfaces (for 
TSc
(12.5)
TSg
(1.2)
unfavorable
steric interactions
favorable
London 
interactions
unfavorable
steric interactions
no steric hindrance
TSa
(0.0)
TSe
(9.1)
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details see SI). As an example, Figure 4 illustrates such an analysis for TSa and TSe in which 
London and π-halogen interactions, respectively, are shown. 
 
 
Figure 4. NCI analysis for TSa and TSe. 
 
Studies on cancer cells  
The development of new chemotherapeutics must take a set of factors into account since cancer 
cells often present intrinsic and acquired mechanisms to evade cytotoxicity. Increased cytoskeleton 
remodelling to support cell motility, mitosis and protein trafficking is a cancer hallmark31 and, after 
a chemotherapy regimen, drug resistance may emerge due to selective killing of sensitive cells. The 
multidrug resistance phenotype (MDR) manifests due to cross-resistance to chemotherapeutic drugs 
with no structural nor functional relationship, markedly by increased activity of ABC superfamily 
transporters.32 In regard to this, and considering that the benzo-1-azaspiro[4.5]decane motif is 
described to present antimitotic properties, all compounds were screened for toxicity towards 
MDA-MB-231, a model of an invasive, poorly differentiated and endocrine therapy-resistant breast 
ductal carcinoma. Results indicated compounds (S)-8d, (S)-8g, (S)-8h, (S)-8i and (R)-8j as 
potential candidates for further studies, since they reduced cell viability to at least 50% after 
treatment with 100 μM for 72 h. Taken these results into account, these compounds, along with 
their respective (S)- or (R)- enantiomers, were further evaluated on two models of human chronic 
myeloid leukemias. K562 cells present constitutive BCR/ABL tyrosine kinase activity leading to a 
highly proliferative status; FEPS is a K562/DNR derivative cell selected after continuous exposure 
of K562 to daunorubicin (DNR),33 cross-resistant to a variety of natural and synthetic compounds 
owing to, but not limited to, its high efflux activity mediated by the ABC transporters ABCB1 
(Pgp) and ABCC1 (MRP1).33,34 The chemotherapeutic drugs vincristine (VCR), a tubulin-binding 
antimitotic alkaloid, and daunorubicin, a pro-oxidant, DNA-alkylating anthracycline were employed 
as controls. The antiproliferative effect of the various compounds on K562 and FEPS cells can be 
observed in Table 3. 
 
TSa TSe
London 
interactions
forming bond forming bond
π‐halogen
interactions
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Table 3. IC50 for the (S)- and (R)-azaspiro derivatives 8d, 8g, 8h, 8i and 8j, as well as for the 
standards VCR and DNR toward human leukemias. 
 
Compound K562 FEPS 
(S)-8d 123.17±9.45 149.20±17.19 
(R)-8d >200 >200 
(S)-8g >200 64.16±8.56 
(R)-8g 142.42±23.51 70.86±16.41 
(S)-8h 124.15±10.40 34.68±3.93 
(R)-8h 59.72±4.23 31.85±3.00 
(S)-8i >200 >200 
(R)-8i >200 154.83±14.77 
(S)-8j 77.58±5.76 47.07±7.08 
(R)-8j 75.52±4.74 33.81±7.55 
VCR* 57.70±9.55 922.25±107.87
DNR* 82.15±2.93 1543.40±134.42
Mean IC50 values ± SEM, in μM, obtained from a range of concentrations after three independent experiments, with 
each concentration evaluated in triplicate. Assays performed as described in the Experimental Section. *For VCR and 
DNR, mean IC50± SEM is expressed in nM. 
 
Results indicate that the evaluated compounds exerted cytotoxicity to both cell subtypes, most 
notably the 7’-bromo (R)-8h and the thiochromanes (S)- and (R)-8j. Moreover, the 7’-fluoro 
derivatives (S)- and (R)-8g and 7’-bromo (S)-8h were effective only on FEPS. The enantiomeric 
conformation produced little effect concerning the pharmacological effect, since only (R)-8h 
seemed to induce two-fold higher toxicity, and limited to K562. Disruption of the mitotic spindle is 
a well-recognized mechanism exerted by chemotherapeutic drugs such as VCR and paclitaxel,35 and 
kinesin spindle proteins (KSP), motor proteins involved in anterograde protein transport and 
mitosis, are important for correct centrosome and chromosome segregation.36 Kinesins have already 
been linked to multidrug resistance,37 and its inhibition induced cell death on drug-resistant ovarian 
cancer38 and lymphomas.39 Since the benzo-1-azaspiro[4.5]decane motif was demonstrated to 
inhibit the KSP KIF11, FEPS present increased gene expression of KIF1A and KIF21B over 
K562,40 and halogen modifications of known KSP inhibitors were shown to increase 
bioavailability41 and to overcome ABC transporter-mediated efflux42 this mechanism seems 
feasible. Intererstingly, all compounds but the 6’-methoxyl (S)- and (R)-8d and the chromane (S)-8i 
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presented higher toxicity to the MDR cell FEPS than to the parental K562. This profile is known as 
collateral sensitivity, and can be described as a hypersensitivity towards secondary drugs that arises 
from the development of resistance towards an unrelated primary agent.43 Figure 5 shows that 
compounds (S)- and (R)-8g, (S)-8h and (R)-8j induced collateral sensitivity on FEPS, since they 
presented RR ≤ 0.5.44 Of note, for the standard drugs VCR and DNR this ratio was higher than 2.0, 
indicative of drug resistance. 
 
Figure 5. Relative resistance (RR) indexes for the azaspiro compounds evaluated on chronic 
myeloid leukemias. RR = (IC50 resistant cell line, FEPS) ⁄ (IC50 parental cell line, K562). When 
IC50 exceeded the maximal tested concentration it was expressed as being higher than this 
concentration (e.g. >200), and this value, 200, was used for calculating the RR (e.g. RR of (R)-8i: 
IC50 FEPS / IC50 K562 = 154.83/200 = 0.77). Similar shapes and colors indicate each azaspiro (S)- 
or (R)- enantiomeric conformations, and the numbers above, the calculated RR for each compound.  
Despite being poorly understood, mechanisms that govern collateral sensitivity may either rely on 
or be independent from MDR mechanisms. ATP depletion after a futile cycle of passive influx and 
active efflux of an ABCB1 transporter substrate, ABCC1-mediated extrusion of endobiotics such as 
glutathione, ROS production after metal-mediated redox cycling and perturbation of cellular 
bioenergetics and/or the plasma membrane fluidity were linked to collateral sensitivity.45 Of note, 
the azaspiro compounds with the lowest RR presented a similar modification, the addition of the 
halogens fluorine or bromine. Halogenation has been previously linked to collateral sensitivity, as 
the addition of bromine,46 chlorine46 and iodine47 on aza-carbapterocarpans produced similar 
outcomes on MDR leukemias. Halogen bonds are ubiquitous in nature, taking part in protein-ligand 
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interactions involving the carbonyl group present on the side chain of every aminoacid, and 
carboxylates in aspartate and glutamate.48 Whether the observed collateral sensitization is a result of 
KSP inhibition, interaction with (or lack thereof) ABC proteins, targeting aminoacids such as the 
glutathione precursor glutamate, of simply by the increased bioavailability granted by the addition 
of halogens, this effect should undergo thorough investigation as it could foster the development of 
MDR-targeting azaspiro compounds. 
 
CONCLUSIONS 
 
Dibenzo-1-azaaspiro[4.5]decanes were prepared in a enantiomerically pure form from tert-
butanesulfinamide, 2-bromobenzylbromide and tetralone type ketones. The methodology presented 
here comprised as key steps a diastereoselective addition of a benzylic organomagnesium 
compound to a chiral sulfinyl ketimine and an intramolecular palladium-catalyzed N-arylation. DFT 
calculations correctly predicted the observed experimental results evidencing that the reaction is 
under kinetic control and the two competitive transition structures resulted from the Si attack to the 
(E)-isomer and the Re attack to the (Z)-isomer. Whereas in the former, the preferred one, the 
presence of stabilizing London interactions contributes to the lowest barrier, in the latter it is the 
absence of any steric hindrance which causes the corresponding barrier to be only 1.2 kcal/mol 
higher in energy. The benzo-1-azaspiro[4.5]decane derivatives were effective on models of 
leukemias with diverse adaptations to evade cytotoxicity, depending on the pattern of substitutions 
on its molecular scaffold. The thiochromane compounds were the most promising, whereas the 
addition of bromine or fluorine produced collateral sensitivity to MDR cells. Our results highlight 
the azaspiro motif as an important lead for the development of new antineoplastic drugs targeted to 
chemo-refractory neoplasias, a sought after profile for the management of cancer. 
 
EXPERIMENTAL SECTION 
General Remarks: tert-Butanesulfinamides (R and S) were a gift of Medalchemy (> 99% ee by 
chiral HPLC on a Chiracel AS column, 90:10 n-hexane/i-PrOH, 1.2 mL/min, λ=222 nm). TLC was 
performed on silica gel 60 F254, using aluminum plates and visualized with phosphomolybdic acid 
(PMA) stain. Flash chromatography was carried out on handpacked columns of silica gel 60 (230- 
400 mesh). Melting points are uncorrected. Optical rotations were measured using a polarimeter 
with a thermally jacketted 5 cm cell at approximately 20 ºC and concentrations (c) are given in 
g/100 mL. Infrared analyses were performed with a spectrophotometer equipped with an ATR 
component; wavenumbers are given in cm-1. Low-resolution mass spectra (EI) were obtained at 70 
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eV; and fragment ions in m/z with relative intensities (%) in parentheses. High-resolution mass 
spectra (HRMS) were also carried out in the electron impact mode (EI) at 70 eV using a quadrupole 
mass analyzer or in the electrospray ionization mode (ESI) using a TOF analyzer. NMR Spectra 
were recorded at 300 or 400 MHz for 1H NMR and 75 or 100 MHz for 13C NMR, using CDCl3 and 
CD3OD as the solvents, and TMS as internal standard (0.00 ppm). 19 F NMR Spectrum for 
compound (RS)-6g was recorded at 282 MHz, using CDCl3 as the solvent, and CF3CO2H as internal 
standard (−75.66 ppm). The data are being reported as: s = singlet, d = doublet, t = triplet, q = 
quadruplet, m = multiplet or unresolved, br s = broad signal, coupling constant(s) in Hz, integration. 
13C NMR spectra were recorded with 1H-decoupling at 100 MHz and referenced to CDCl3 at 77.16 
ppm. DEPT-135 experiments were performed to assign CH, CH2 and CH3. 
 
General Procedure for the Synthesis of N-tert-Butanesulfinyl Imines 4a-h from Tetralones 2a-
h and tert-Butanesulfinamide (1): The corresponding tetralone 2 (2.0 mmol), (R)- or (S)-tert-
butanesulfinamide [(R)-1 or (S)-1, 338.8 mg, 2.80 mmol], and Ti(OEt)4 (912 mg, 0.84 mL, 4.0 
mmol) were mixed and stirred under argon at room temperature. The reaction vessel was placed 
into the microwave reactor and heated to 70 °C (constant microwave irradiation at 40 W) for 90 
min. After cooling to room temperature, the mixture was diluted with EtOAc (10 mL) and poured 
into 0.5 mL of brine while being rapidly stirred. The resulting suspension was filtered through a 
plug of Celite, and the filter cake was washed with EtOAc (20 mL). After evaporation of the solvent 
(15 Torr), the residue was purified by column chromatography (silica gel, hexane/EtOAc) to yield 
products 4a-h. Yields, physical and spectroscopic data follow. 
(RS)-N-(tert-Butanesulfinyl)-3,4-dihydronaphthalen-1(2H)-imine [(RS)-4a]:49 The representative 
procedure was followed by using tetralone 2a (731.0 mg, 0.665 mL, 5.00 mmol) and (R)-tert-
butanesulfinamide [(R)-1, 847.0 mg, 7.00 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (RS)-4a (510.5 mg, 2.05 mmol, 41%) as a yellow oil;  [α]D20 = −24.2 (c 
= 0.56, CH2Cl2); Rf = 0.27 (hexane/EtOAc, 3:1); IR ν (neat) 2933, 2856, 1479, 1294, 1159, 1081, 
1061, 781, 723 cm–1; δH 8.17 (dd, J = 8.0, 1.3 Hz, 1H), 7.39 (td, J = 7.5, 1.4 Hz, 1H), 7.25 (t, J = 7.6 
Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 3.33–3.24 (m, 1H), 3.10–3.01 (m, 1H), 2.91–2.84 (m, 2H), 2.90–
2.85 (m, 2H), 1.33 (s, 9H); δC 177.1 (C), 142.3 (C), 133.1 (C), 132.1 (CH), 129.0 (CH), 127.1 (CH), 
126.6 (CH), 57.2 (C), 32.5 (CH2), 29.6 (CH2), 22.8 (CH2), 22.6 (CH3); LRMS (EI) m/z 249 (M+, 
0.2%), 194 (13), 193 (100), 145 (44), 144 (18), 117 (32), 116 (19), 57 (18). 
(RS)-N-(tert-Butanesulfinyl)-4-methyl-3,4-dihydronaphthalen-1(2H)-imine [(RS)-4b]: The 
representative procedure was followed by using 4-methyltetralone 2b (400.0 mg, 2.50 mmol) and 
(R)-tert-butanesulfinamide [(R)-1, 423.5 mg, 3.50 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (RS)-4b (328.8 mg, 1.25 mmol, 50%) as a mixture of diastereoisomers 
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(1:1); yellow oil; Rf = 0.67 (hexane/EtOAc, 1:1); IR ν (neat) 2959, 1685, 1456, 1360, 1294, 1159, 
1072, 1054, 1011, 764, 721, 690 cm–1; δH 8.16 (d, J = 7.5 Hz, 1H), 7.46–7.39 (m, 1H), 7.31–7.22 
(m, 2H), 3.39–3.34 (m 2H), 3.06–3-02 (m, 2H), 2.16–2.10 (m, 1H), 1.77–1.72 (m, 1H), 1.34 (s, 
9H); δC 177.3 (C), 147.0 (C), 132.4 (CH), 127.8 (CH), 127.2 (CH), 127.4 (CH), 127.2 (CH), 126.5 
(CH), 57.1 (C), 32.6 (CH), 30.2 (CH2), 30.0 (CH2), 29.7 (CH2), 29.3 (CH2) 22.6 (CH3), 20.9 (CH3), 
20,7 (CH3); LRMS (EI) m/z 263 (M+, 0.2%), 208 (13), 207 (100), 159 (14), 144 (33), 130 (15), 57 
(12); HRMS (ESI-TOF) m/z: (M+H)+ Calcd for C15H22NOS 264.1422; Found 264.1424. 
(RS)-N-(tert-Butanesulfinyl)-5-methoxy-3,4-dihydronaphthalen-1(2H)-imine [(RS)-4c]:50 The 
representative procedure was followed by using 5-methoxytetralone 2c (530.0 mg, 3.00 mmol) and 
(R)-tert-butanesulfinamide [(R)-1, 508.2 mg, 4.20 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (RS)-4c (452.0 mg, 1.62 mmol, 54%) as a yellow solid; mp 88–92 ºC 
(hexane/CH2Cl2); [α]D20 = −39.1 (c = 0.58, CH2Cl2); Rf = 0.35 (hexane/EtOAc, 1:1); IR ν (neat) 
3078, 2962, 2933, 1571, 1440, 1256, 1120, 1061, 790, 712 cm–1; δH 7.79 (d, J = 7.3 Hz, 1H), 7.21 
(t, J = 8.1 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 3.85 (s, 3H), 3.30–3.26 (m, 1H), 3.06–3.03 (m, 1H), 
2.79–2.75 (m, 2H), 2.00–1.96 (m, 2H), 1.32 (s, 9H); δC 177.2 (C), 156.9 (C), 134.2 (C), 131.5 (C), 
126.5 (CH), 118.9 (CH), 112.9 (CH), 57.3 (C), 55.7 (CH3), 32.0 (CH2), 22.6 (CH3), 22.6 (CH2), 
22.1 (CH2); LRMS (EI) m/z 279 (M+, 0.2%), 223 (52), 175 (100), 147 (13), 57 (10). 
(RS)-N-(tert-Butanesulfinyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-imine [(RS)-4d]:49 The 
representative procedure was followed by using 6-methoxytetralone 2d (883.0 mg, 5.00 mmol) and 
(R)-tert-butanesulfinamide [(R)-1, 847.0 mg, 7.00 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (RS)-4d (390.6 mg, 1.40 mmol, 28%) as a yellow oil; [α]D20 = −11.0 (c 
= 0.32, CH2Cl2); Rf = 0.11 (hexane/EtOAc, 3:1); IR ν (neat) 3059, 2962, 1575, 1469, 1440, 1256, 
1178, 1061, 1032, 790 cm–1; δH 8.16 (d, J = 8.9 Hz, 1H), 6.79 (dd, J = 8.9, 2.7 Hz, 1H), 6.65 (d, J = 
2.6 Hz, 1H), 3.33–3.15 (m, 1H), 3.07–2.91 (m, 1H), 2.84 (t, J = 6.1 Hz, 2H), 2.14–1.88 (m, 2H), 
1.31 (s, 9H); δC 176.9 (C), 162.7 (C), 144.6 (C), 129.3 (CH), 126.3 (C), 113.4 (CH), 112.7 (CH), 
56.8 (C), 55.4 (CH3), 32.4 (CH2), 30.0 (CH2), 22.8 (CH2), 22.5 (CH3); LRMS (EI) m/z 279 (M+, 
0.4%), 223 (69), 222 (15), 175 (100), 147 (39), 57 (10). 
(RS)-N-(tert-Butanesulfinyl)-7-methoxy-3,4-dihydronaphthalen-1(2H)-imine [(RS)-4e]:49 The 
representative procedure was followed by using 7-methoxytetralone 2e (704.0 mg, 4.00 mmol) and 
(R)-tert-butanesulfinamide [(R)-1, 677.6 mg, 5.60 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (RS)-4e (480.0 mg, 1.72 mmol, 43%) as a yellow oil; [α]D20 = +12.4 (c 
= 0.53, CH2Cl2); Rf = 0.22 (hexane/EtOAc, 3:1); IR ν (neat) 2942, 2865, 1556, 1488, 1226, 1072, 
1032, 809, 702 cm–1; δH 7.67 (d, J = 2.8 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.96 (dd, J = 8.4, 2.8 Hz, 
1H), 3.79 (s, 3H), 3.24–3.19 (m, 1H), 2.99–2.95 (m, 1H), 2.79 (t, J = 6.1 Hz, 2H), 2.04–1.88 (m, 
2H), 1.30 (s, 9H); δC 177.0 (C), 158.1 (C), 135.0 (C), 133.9 (C), 130.1 (CH), 119.6 (CH), 110.1 
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(CH), 57.3 (C), 55.4 (CH3), 32.3 (CH2), 28.8 (CH2), 23.1 (CH2), 22.6 (CH3); LRMS (EI) m/z 279 
(M+, 0.4%), 223 (72), 175 (100), 174 (99), 146 (29), 145 (23), 57 (17). 
(RS)-N-(tert-Butanesulfinyl)-6,7-dimethoxy-3,4-dihydronaphthalen-1(2H)-imine [(RS)-4f]:51 
The representative procedure was followed by using 6,7-dimethoxytetralone 2f (338.0 mg, 2.80 
mmol) and (R)-tert-butanesulfinamide [(R)-1, 474.3 mg, 3.92 mmol]. Purification by column 
chromatography (hexane/AcOEt, 4:1) yielded (RS)-4f (251.0 mg, 0.81 mmol, 29%) as a yellow oil; 
[α]D20 = +2.4 (c = 0.54, CH2Cl2); Rf = 0.20 (hexane/EtOAc, 1:1); IR ν (neat) 2992, 2929, 1552, 
1508, 1363, 1273, 1258, 1141, 1054, 1030, 805 cm–1; δH 7.72 (s, 1H), 6.62 (s, 1H), 3.92 (s, 3H), 
3.89 (s, 3H), 3.30–3.17 (m, 1H), 3.0 –2.90 (m, 1H), 2.82 (t, J = 6.1 Hz, 2H), 2.10–1.91 (m, 2H), 
1.31 (s, 9H); δC 176.6 (C), 152.8 (C), 147.7 (C), 137.0 (C), 125.7 (C), 110.5 (CH), 108.6 (CH), 56.9 
(C), 55.0 (CH3), 55.9 (CH3), 32.0 (CH2), 29.3 (CH2), 23.1 (CH2), 22.5 (CH3); LRMS (EI) m/z 309 
(M+, 0.8%), 253 (72), 252 (33), 205 (100), 190 (22), 176 (23), 159 (19), 57 (13). 
(RS)-N-(tert-Butanesulfinyl)-7-fluoro-3,4-dihydronaphthalen-1(2H)-imine [(RS)-4g]: The 
representative procedure was followed by using 7-fluorotetralone 2g (450.0 mg, 2.70 mmol) and 
(R)-tert-butanesulfinamide [(R)-1, 457.4 mg, 3.78 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (RS)-4g (510.0 mg, 1.91 mmol, 71%) as a yellow oil; [α]D20 = –3.9 (c = 
0.41, CH2Cl2); Rf = 0.18 (hexane/EtOAc, 3:1); IR ν (neat) 2928, 2239, 1580, 1483, 1270, 1067, 902, 
814, 727 cm–1; δH 7.81 (dd, J = 10.1, 2.7 Hz, 1H), 7.22–7.00 (m, 2H), 3.27 (ddd, J = 17.6, 9.1, 4.8 
Hz, 1H), 3.05 (ddd, J = 17.7, 7.2, 4.6 Hz, 1H), 2.84 (t, J = 6.1 Hz, 2H), 2.10–1.85 (m, 2H), 1.33 (s, 
9H); δC 175.9 (C), 161.4 (d, J = 244.4 Hz, C), 137.9 (d, J = 2.8 Hz, C), 134.7 (C), 130.6 (d, J = 7.3 
Hz, CH), 119.4 (d, J = 22.2 Hz, CH), 112.9 (d, J = 22.7 Hz, CH), 57.5 (C), 32.06 (CH2), 28.9 
(CH2), 22.8 (CH2), 22.6 (CH3); LRMS (EI) m/z 267 (M+, 1%), 211 (91), 163 (57), 135 (29), 134 
(20), 57 (55), 43 (100); HRMS (ESI-TOF) m/z: (M+H)+ Calcd for C14H19FNOS 268.1171; Found 
268.1163.  
(RS)-7-Bromo-N-(tert-butanesulfinyl)-3,4-dihydronaphthalen-1(2H)-imine [(RS)-4h]:49 The 
representative procedure was followed by using 7-bromotetralone 2h (450.0 mg, 1.99 mmol) and 
(R)-tert-butanesulfinamide [(R)-1, 339.0 mg, 2.80 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (RS)-4h (475.6 mg, 1.45 mmol, 73%) as a yellow solid; mp 95–98 ºC 
(hexane/CH2Cl2); [α]D20 = +24.2 (c = 0.21, CH2Cl2); Rf = 0.19 (hexane/EtOAc, 3:1); IR ν (neat) 
2938, 1483, 1261, 1173, 1047, 902, 805, 727 cm–1; δH 8.24 (d, J = 2.2 Hz, 1H), 7.48 (dd, J = 8.2, 
2.2 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 3.27 (ddd, J = 17.6, 9.1, 5.0 Hz, 1H), 3.04 (ddd, J = 17.6, 7.3, 
4.6 Hz, 1H), 2.81 (t, J = 6.1 Hz, 2H), 2.08–1.89 (m, 2H), 1.33 (s, 3H); δC 175.5 (C), 141.0 (C), 
134.7 (C), 134.7 (CH), 130.8 (CH), 129.7 (CH), 120.5 (C), 57.5 (C), 32.1 (CH2), 29.1 (CH2), 22.5 
(CH3), 22.4 (CH2); LRMS (EI) m/z 328 (M+, 0.04%), 273 (100), 271 (98), 225 (48), 223 (50), 57 
(38). 
Page 17 of 37
ACS Paragon Plus Environment
The Journal of Organic Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(SS)-N-(tert-Butanesulfinyl)-3,4-dihydronaphthalen-1(2H)-imine [(SS)-4a]:49 The representative 
procedure was followed by using tetralone 2a (600.0 mg, 0.540 mL, 4.10 mmol) and (S)-tert-
butanesulfinamide [(S)-1, 694.5 mg, 5.74 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (SS)-4a (418.5 mg, 1.68 mmol, 41%). Physical and spectroscopic data 
were found to be same than for (RS)-4a. [α]D20 = +22.7 (c = 0.51, CH2Cl2). 
(SS)-N-(tert-Butanesulfinyl)-5-methoxy-3,4-dihydronaphthalen-1(2H)-imine [(SS)-4c]:50 The 
representative procedure was followed by using 5-methoxytetralone 2c (600.0 mg, 3.40 mmol) and 
(S)-tert-butanesulfinamide [(S)-1, 576.0 mg, 4.76 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (SS)-4c (436.3 mg, 1.56 mmol, 46%). Physical and spectroscopic data 
were found to be same than for (RS)-4c. [α]D20 = +14.9 (c = 0.38, CH2Cl2). 
(SS)-N-(tert-Butanesulfinyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-imine [(SS)-4d]:49 The 
representative procedure was followed by using 6-methoxytetralone 2d (600.0 mg, 3.40 mmol) and 
(S)-tert-butanesulfinamide [(S)-1, 567.0 mg, 4.76 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (SS)-4d (379.4 mg, 1.36 mmol, 40%). Physical and spectroscopic data 
were found to be same than for (RS)-4d. [α]D20 = +4.5 (c = 0.45, CH2Cl2). 
(SS)-N-(tert-Butanesulfinyl)-7-methoxy-3,4-dihydronaphthalen-1(2H)-imine [(SS)-4e]:49 The 
representative procedure was followed by using 7-methoxytetralone 2e (600.0 mg, 3.40 mmol) and 
(S)-tert-butanesulfinamide [(S)-1, 576.0 mg, 4.76 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (SS)-4a (417.4 mg, 1.47 mmol, 44%). Physical and spectroscopic data 
were found to be same than for (RS)-4e. [α]D20 = –7.2 (c = 0.35, CH2Cl2). 
(SS)-N-(tert-Butanesulfinyl)-6,7-dimethoxy-3,4-dihydronaphthalen-1(2H)-imine [(SS)-4f]:51 The 
representative procedure was followed by using 6,7-dimethoxytetralone 2f (600.0 mg, 2.91 mmol) 
and (S)-tert-butanesulfinamide [(S)-1, 363.0 mg, 3.00 mmol]. Purification by column 
chromatography (hexane/AcOEt, 4:1) yielded (SS)-4f (269.7 mg, 0.873 mmol, 30%). Physical and 
spectroscopic data were found to be same than for (RS)-4f. [α]D20 = –1.5 (c = 0.43, CH2Cl2).  
(SS)-N-(tert-Butanesulfinyl)-7-fluoro-3,4-dihydronaphthalen-1(2H)-imine [(SS)-4g]: The 
representative procedure was followed by using 7-fluorotetralone 2g (450.0 mg, 2.74 mmol) and 
(S)-tert-butanesulfinamide [(S)-1, 508.0 mg, 4.20 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (SS)-4g (585.3 mg, 2.19 mmol, 80%). Physical and spectroscopic data 
were found to be same than for (RS)-4g. [α]D20 = +13.8 (c = 0.59, CH2Cl2). 
(SS)-7-Bromo-N-(tert-butanesulfinyl)-3,4-dihydronaphthalen-1(2H)-imine [(SS)-4h]:49 The 
representative procedure was followed by using 7-bromotetralone 2h (450.0 mg, 1.99 mmol) and 
(S)-tert-butanesulfinamide [(S)-1, 339.0 mg, 2.80 mmol]. Purification by column chromatography 
(hexane/AcOEt, 4:1) yielded (SS)-4h (509.1 mg, 1.55 mmol, 78%). Physical and spectroscopic data 
were found to be same than for (RS)-4h. [α]D20 = –30.7 (c = 0.48, CH2Cl2). 
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 General Procedure for the Synthesis of N-tert-Butanesulfinyl Imines 4i,j from Chromanone 
(2i) and Thiochromanone (2j), and tert-Butanesulfinamide (1): A mixture of tert-
butanesulfinamide [(R)-1 or (S)-1, 339.0 mg, 2.8 mmol], the corresponding ketone 2 (2.0 mmol) and 
Ti(OEt)4 (912 mg, 0.84 mL, 4.0 mmol) in THF (8 mL) was stirred for 12 h at 66 ºC. Then, the 
resulting mixture was hydrolyzed with brine (8 mL), extracted with EtOAc (3 × 10 mL), dried over 
anhydrous MgSO4 and evaporated (15 Torr). The residue was purified by column chromatography 
(silica gel, hexane/EtOAc) to yield products 4i,j. Yields, physical and spectroscopic data follow. 
(RS)-N-(tert-Butanesulfinyl)chroman-4-imine [(RS)-4i]:49 The representative procedure was 
followed by using 4-chromanone 2i (592.6 mg, 4.00 mmol) and (R)-tert-butanesulfinamide [(R)-1, 
677.6 mg, 5.60 mmol]. Purification by column chromatography (hexane/AcOEt, 4:1) yielded (RS)-
4i (722.8 mg, 2.88 mmol, 72%) as a yellow oil; [α]D20 = –75.3 (c = 0.56, CH2Cl2); Rf = 0.27 
(hexane/EtOAc, 3:1); IR ν (neat) 2982, 2913, 1611, 1587, 1454, 1306, 1258, 1214, 1077, 1055, 
1041, 760 cm–1; δH 8.04–7.96 (m, 1H), 7.42–7.34 (m, 1H), 7.01–6.88 (m, 2H), 4.43–4.25 (m, 2H), 
3.56–3.44 (m, 1H), 3.34–3.21 (m, 1H), 1.33 (s, 9H); δC 169.7 (C), 159.3 (C), 134.3 (CH), 127.0 
(CH), 121.4 (CH), 121.1 (C), 118.0 (CH), 65.6 (CH2), 58.0 (C), 30.7 (CH2), 22.7 (CH3); LRMS (EI) 
m/z 251 (M+, 0.2%), 195 (41), 147 (48), 57 (22), 43 (100). 
(RS)-N-(tert-Butanesulfinyl)thiochroman-4-imine [(RS)-4j]:49 The representative procedure was 
followed by using 4-thiochromanone 2j (600.0 mg, 3.65 mmol) and (R)-tert-butanesulfinamide 
[(R)-1, 618.3 mg, 5.11 mmol]. Purification by column chromatography (hexane/AcOEt, 4:1) 
yielded (RS)-4j (760.1 mg, 2.85 mmol, 78%) as a yellow solid; mp 76–79 ºC  (hexane/CH2Cl2); 
[α]D20 = −95.0 (c = 0.39, CH2Cl2); Rf = 0.23 (hexane/EtOAc, 3:1); IR ν (neat) 2977, 2918, 1565, 
1430, 1323, 1149, 1042, 761, 723, 678 cm–1; δH 8.18 (d, J = 9.4 Hz, 1H), 7.33–7.07 (m, 3H), 3.73–
3.60 (m, 1H), 3.51–3.37 (m, 1H), 3.10 (t, J = 6.4 Hz, 2H), 1.33 (s, 9H); δC 172.7 (C), 139.2 (C), 
131.8 (CH2), 131.4 C), 128.9 (CH2), 128.1 (CH2), 125.0 (CH2), 58.0 (C), 32.5 (CH2), 25.9 (CH2), 
22.7 (CH3); LRMS (EI) m/z 267 (M+, 0.7%), 211 (76), 163 (100), 135 (42), 57 (27). 
(SS)-N-(tert-Butanesulfinyl)chroman-4-imine [(SS)-4i]:49 The representative procedure was 
followed by using 4-chromanone 2i (600.0 mg, 4.04 mmol) and (S)-tert-butanesulfinamide [(S)-1, 
677.8 mg, 5.60 mmol]. Purification by column chromatography (hexane/AcOEt, 4:1) yielded (SS)-4i 
(861.9 mg, 3.43 mmol, 85%). Physical and spectroscopic data were found to be same than for (RS)-
4i. [α]D20 = +89.4 (c = 0.63, CH2Cl2). 
(SS)-N-(tert-Butanesulfinyl)thiochroman-4-imine [(SS)-4j]:49 The representative procedure was 
followed by using 4-thiochromanone 2j (600.0 mg, 3.65 mmol) and (S)-tert-butanesulfinamide [(S)-
1, 618.3 mg, 5.11 mmol]. Purification by column chromatography (hexane/AcOEt, 4:1) yielded 
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(SS)-4h (760.0 mg, 2.85 mmol, 78%). Physical and spectroscopic data were found to be same than 
for (RS)-4j. [α]D20 = +89.2 (c = 0.34, CH2Cl2). 
 
General Procedure for the Reaction of 2-Bromobenzylmagnesium Bromide (5) 2 with N-tert-
Butanesulfinyl Imines 4. Synthesis of Compounds 6: To a solution of the corresponding imine 4 
(1.0 mmol) in dry toluene (4 mL) was added dropwise a 1M solution of 2-bromobenzylmagnesium 
bromide (5) in diethyl ether (3.0 mmol, 3.0 mL) at -78 ºC. The reaction mixture was allowed to 
reach room temperature for 12 h, and after that, it was cooled down to 0 ºC, hydrolyzed with water 
(5 mL) and extracted with EtOAc (4 × 15 mL). The organic layers were successively washed with 
water (15 mL), brine (10 mL) and then dried with anhydrous MgSO4, and the solvent evaporated 
(15 Torr). The residue was purified by column chromatography (silica gel, hexane/EtOAc) to yield 
products 6. Yields are given on Table 1, physical and spectroscopic data follow. 
(RS,1S)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-1,2,3,4-tetrahydronaphthalen-1-amine 
[(RS)-6a]: The representative procedure was followed by using imine (RS)-4a (200.0 mg, 0.80 
mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (RS)-6a (268.1 mg, 
0.64 mmol, 80%) as a yellow oil; [α]D20 = −24.2 (c = 0.56, CH2Cl2); Rf = 0.37 (hexane/EtOAc, 3:1); 
IR ν (neat) 2929,2869, 1469, 1241, 1731, 1043, 908, 761, 728 cm–1; δH 7.57 (dd, J = 7.9, 1.1 Hz, 
1H), 7.32 (d, J = 7.8 Hz, 1H), 7.22–7.01 (m, 7H), 3.63 (s, 1H), 3.49 (d, J = 13.9 Hz, 1H), 3.29 (d, J 
= 13.9 Hz, 1H), 2.97–2.84 (m, 1H), 2.73 (dt, J = 16.6, 4.9 Hz, 1H), 2.40 (ddd, J = 14.1, 10.8, 3.4 
Hz, 1H), 2.22 (ddd, J = 14.0, 6.0, 2.6 Hz, 1H), 2.04–192 (m , 2H), 1.19 (s, 9H); δC 139.0 (C), 138.8 
(C), 136.2 (C), 133.2 (CH), 132.9 (CH), 129.2 (CH), 128.9 (CH), 128.7 (CH), 127.2 (CH), 127.1 
(CH), 126.6 (C), 125.6 (CH), 61.7 (C), 56.8 (C), 48.1 (CH2), 36.6 (CH2), 30.1 (CH2), 22.9 (CH3), 
20.3 (CH2); LRMS (EI) m/z 302 (M+−t-BuSONH2, 17%), 301 (97), 299 (100), 250 (30), 194 (65), 
176 (35), 171 (51), 169 (51), 129 (49), 117 (88), 57 (26); HRMS (ESI-TOF) m/z: (M+H)+ Calcd for 
C21H27BrNOS 420.0997; Found 420.0991. 
(RS,1S,4R*)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-4-methyl-1,2,3,4-
tetrahydronaphthalen-1-amine [(RS)-6b]: The representative procedure was followed by using 
imine (RS)-4b (288.0 mg, 1.09 mmol). Purification by column chromatography (hexane/AcOEt, 
2:1) yielded (RS)-6b (221.8 mg, 0.51 mmol, 47%) as a mixture of diastereoisomers (1:1); yellow 
oil; Rf = 0.72 (hexane/EtOAc, 1:1); IR ν (neat) 2952, 2865, 1455, 1375, 1187, 1055, 1027, 1010, 
771, 760 cm–1; δH 7.57 (d, J = 6.4 Hz, 2H), 7.38–7.30 (m, 2H), 7.27–7.05 (m, 5H), 7.00 (dd, J = 7.6, 
1.8 Hz, 1H), 3.58 (s, 1H), 3.56 (d, J = 2.1 Hz, 1H), 3.52 (s, 1H), 3.41 (d, J = 13.9 Hz, 1H), 3.32 (d, 
J = 13.9 Hz, 1H), 3.25 (d, J = 13.9 Hz, 1H), 3.04–2.87 (m, 2H), 2.67–2.54 (m, 1H), 2.40–2.22 (m, 
2H), 2.20–2.04 (m, 4H), 1.81–1.63 (m, 3H), 1.42 (d, J = 9.7 Hz, 1H), 1.36 (d, J = 7.2 Hz, 3H), 1.20 
(s, 8H), 1.18 (s, 10H); δC 138.7 (C), 138.3 (C), 133.2 (C), 133.1 (C), 131.0 (C), 130.9 (C), 128.0 
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(CH), 127.9 (CH), 127.7 (CH), 127.4 (CH), 123.6 (CH), 123.5 (CH), 123.4 (CH), 123.3 (CH), 
122.5 (CH), 122.1 (CH), 122.1 (CH), 121.8 (CH), 121.7 (CH), 121.4 (C), 121.3 (C), 120.3 (CH), 
120.2 (CH), 56.4 (C), 56.3 (C), 51.5 (C), 51.4 (C), 42.8 (CH2), 42.6 (CH2), 28.7 (CH2), 27.6 (CH), 
26.4 (CH2), 23.1 (CH2), 22.2 (CH2), 18.1 (CH3), 17.6 (CH3), 16.6 (CH3); LRMS (EI) m/z 316 (M+–
t-BuSONH2, 19%), 171(45), 169 (47), 144 (29), 143 (44), 131(53), 57 (40); HRMS (ESI-TOF) m/z: 
(M+H)+ Calcd for C22H29BrNOS 434.1153; Found 434.1144. 
(RS,1S)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-
amine [(RS)-6c]: The representative procedure was followed by using imine (RS)-4c (390.0 mg, 
1.39 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (RS)-6c (312.0 
mg, 0.69 mmol, 50%) as a yellow oil; [α]D20 = –69.8 (c = 0.38, CH2Cl2); Rf = 0.21 (hexane/EtOAc, 
3:1); IR ν (neat) 2952, 2865, 1586, 1430, 1256, 1042, 7 23, 702 cm–1; δH 7.58–7.52 (m, 1H), 7.22–
6.95 (m, 5H), 6.74 (d, J = 8.0 Hz, 1H), 3.81 (s, 3H), 3.57 (s, 1H), 3.51 (d, J = 13.9 Hz, 1H), 3.30 (d, 
J = 13.9 Hz, 1H), 2.78–2.55 (m, 2H), 2.39–2.29 (m, 1H), 2.21–2.09 (m, 1H), 1.99–1.85 (m, 1H), 
1.18 (s, 9H); δC 157.0 (C), 140.5 (C), 136.4 (C), 133.3 (CH), 133.1 (CH), 128.8 (CH), 128.2 (C), 
127.2 (CH), 126.7 (C), 125.8 (CH), 120.8 (CH), 108.2 (CH), 61.6 (C), 56.9 (C), 55.4 (CH3), 47.8 
(CH2), 36.0 (CH2), 23.4 (CH2), 23.0 (CH3), 19.6 (CH2); LRMS (EI) m/z 332 (M+–t-BuSONH2, 
19%), 330 (22), 329 (100), 280 (27), 224 (58), 175 (38), 171 (38), 169 (40), 159 (46), 147 (78), 121 
(40), 57 (24); HRMS (ESI-TOF) m/z: (M+H)+ Calcd for C22H29BrNO2S 450.1102; Found 450.1099. 
(RS,1S)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-
amine [(RS)-6d]: The representative procedure was followed by using imine (RS)-4d (367.0 mg, 
1.31 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (RS)-6d (175.1 
mg, 0.39 mmol, 30%) as a yellow oil; [α]D20 = –6.5 (c = 0.51, CH2Cl2); Rf = 0.31 (hexane/EtOAc, 
1:1); IR ν (neat) 2928, 2831, 1606, 1464, 1439, 1243, 1024, 756, 818 cm–1; δH 7.57 (dd, J = 8.0, 1.3 
Hz, 1H), 7.24–7.14 (m, 2H), 7.14–7.01 (m, 2H), 6.78–6.68 (m, 1H), 6.62 (d, J = 2.7 Hz, 1H), 3.81 
(s, 4H), 3.55 (s, 1H), 3.45 (d, J = 13.9 Hz, 1H), 3.26 (d, J = 13.9 Hz, 1H), 2.96–2.84 (m, 1H), 2.70 
(dt, J = 16.6, 5.0 Hz, 1H), 2.44–2.29 (m, 1H), 2.25–2.12 (m, 1H), 2.02–1.87 (m, 2H), 1.19 (s, 9H); 
δC 158.5 (C), 140.4 (C), 136.5 (C), 133.3 (CH), 133.1 (CH), 131.1 (C), 130.4 (CH), 128.8 (CH), 
127.2 (CH), 126.7 (C), 113.0 (CH), 112.6 (CH), 61.4 (C), 56.8 (C), 55.2 (CH3), 48.3 (CH2), 37.0 
(CH2), 30.6 (CH2), 23.0 (CH3), 20.5 (CH2); LRMS (EI) m/z 332 (M+–t-BuSONH2, 19%), 331 (99), 
330 (28), 329 (100), 280 (45), 224 (67), 176 (85), 175 (42), 159 (40), 147 (58), 57 (22); HRMS 
(ESI-TOF) m/z: (M+H)+ Calcd for C22H29BrNO2S 450.1102; Found 450.1101. 
(RS,1S)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-7-methoxy-1,2,3,4-tetrahydronaphthalen-1-
amine [(RS)-6e]: The representative procedure was followed by using imine (RS)-4e (397.0 mg, 
1.42 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (RS)-6e (388.9 
mg, 0.86 mmol, 61%) as a yellow oil; [α]D20 = –93.5 (c = 0.20, CH2Cl2); Rf = 0.41 (hexane/EtOAc; 
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1:1), IR ν (neat) 2943, 2865, 1734, 1466, 1266, 1236, 1040, 761, 732 cm–1; δH 7.57 (d, J = 8.0 Hz, 
1H), 7.20 (t, J = 8.1 Hz, 1H), 7.14–7.00 (m, 3H), 6.77 (d, J = 8.1 Hz, 2H), 3.66 (s, 3H), 3.59 (s, 
1H), 3.47 (d, J = 13.8 Hz, 2H), 3.26 (d, J = 13.8 Hz, 1H), 2.89–2.78 (m, 1H), 2.69 (dt, J = 16.1, 4.7 
Hz, 1H), 2.43 (ddd, J = 14.3, 11.1, 3.5 Hz, 1H), 2.27–2.16 (m, 2H), 2.04–1.90 (m, 2H), 1.20 (s, 
9H); δC 157.4 (C), 139.8 (C), 136.4 (C), 133.3 (CH),133.2 (CH), 131.1 (C), 130.3 (CH), 128.8 
(CH),127.2 (CH), 126.8 (C), 114.1 (CH), 113.4 (CH), 62.0 (C), 56.9 (C), 55.2 (CH3), 48.3 (CH2), 
37.1 (CH2), 29.4 (CH2), 23.1 (CH3), 20.6 (CH2); LRMS (EI) m/z 332 (M+–t-BuSONH2, 19%), 331 
(98), 330 (23), 329 (100), 224 (48), 206 (22), 175 (20), 174 (41), 159 (40), 57 (21); HRMS (ESI-
TOF) m/z: (M+H)+ Calcd for C22H29BrNO2S 450.1102; Found 450.1106. 
(RS,1S)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-6,7-dimethoxy-1,2,3,4-
tetrahydronaphthalen-1-amine [(RS)-6f]: The representative procedure was followed by using 
imine (RS)-4f (119.0 mg, 0.38 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) 
yielded (RS)-6f (94.6 mg, 0.197 mmol, 52%) as a yellow oil; [α]D20 = –55.9 (c = 0.27, CH2Cl2); Rf = 
0.20 (hexane/EtOAc, 1:1); IR ν (neat) 3011, 2923, 1615, 1509, 1463, 1353, 1254, 1213, 1024, 791 
cm–1; δH 7.55 (dd, J = 8.0, 1.2 Hz, 1H), 7.19 (td, J = 7.4, 1.2 Hz, 1H), 7.08 (ddd, J = 24.7, 7.7, 1.8 
Hz, 2H), 6.59 (d, J = 13.7 Hz, 2H), 3.88 (s, 3H), 3.77 (s, 1H), 3.63 (s, 3H), 3.48 (d, J = 13.9 Hz, 
1H), 3.24 (d, J = 13.9 Hz, 1H), 2.88–2.82 (m, 1H), 2.70–2.65 (m, 1H), 2.48–2.42 (m, 1H), 2.27–
2.22 (m, 1H), 2.09–1.98 (m, 2H), 1.21 (s, 9H); δC 148.3 (C), 146.6 (C), 136.5 (C), 133.2 (CH), 
133.3 (CH), 131.6 (C), 130.0 (C), 128.7 (CH), 127.2 (CH), 126.8 (C) 111.8 (CH), 111.3 (CH), 61.8 
(C), 56.8 (C), 55.8 (CH3), 55.6 (CH3), 48.4 (CH2), 37.8 (CH2), 29.9 (CH2), 23.0 (CH3), 20.8 (CH2); 
LRMS (EI) m/z 362 (M+–t-BuSONH2, 22%), 361(98), 360 (32), 359 (100), 310 (70), 254 (59), 206 
(43), 205 (50), 204 (35), 190 (66), 57 (26); HRMS (ESI-TOF) m/z: (M+H)+ Calcd for 
C23H31BrNO3S 480.1208; Found 480.1207. 
(RS,1S)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-7-fluoro-1,2,3,4-tetrahydronaphthalen-1-
amine [(RS)-6g]: The representative procedure was followed by using imine (RS)-4g (513.0 mg, 
1.92 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (RS)-6g (545.3 
mg, 1.24 mmol, 65%) as a colourless oil; [α]D20  = –54.7 (c = 0.45, CH2Cl2); Rf = 0.30 
(hexane/EtOAc, 3:1); IR ν (neat) 2947, 1610, 1483, 1251, 1047, 912, 727 cm–1; δH 7.59 (dd, J = 7.9, 
1.3 Hz, 1H), 7.28–7.19 (m, 1H), 7.11 (p, J = 7.7 Hz, 3H), 7.00–6.85 (m, 2H), 3.61 (s, 1H), 3.41 (d, 
J = 13.9 Hz, 1H), 3.25 (d, J = 13.9 Hz, 1H), 2.90–2.69 (m, 2H), 2.48–2.17 (m, 2H), 2.03 (d, J = 8.8 
Hz, 2H), 1.21 (s, 9H); δC 160.8 (d, J = 242.8 Hz, C), 141.0 (d, J = 6.3 Hz, C), 135.7 (C), 134.4 (d, J 
= 2.7 Hz, C), 133.4 (CH), 133.0 (CH), 130.6 (d, J = 7.6 Hz, CH), 129.0 (CH), 127.2 (CH), 126.5 
(CH), 115.21 (d, J = 22.0 Hz, CH), 114.6 (d, J = 21.3 Hz, CH), 61.6 (C), 57.0 (C), 47.9 (CH2), 36.4 
(CH2), 29.3 CH2), 22.9 (CH3), 20.4 (CH2); δF –116.84 (1F); LRMS (EI) m/z 320 (M+–t-BuSONH2, 
Page 22 of 37
ACS Paragon Plus Environment
The Journal of Organic Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18%), 319 (98), 318 (20), 317 (100), 212 (68), 171 (77), 169 (78), 147 (44), 135 (74), 57 (38); 
HRMS (ESI-TOF) m/z: (M+H)+ Calcd for C21H26BrFNOS 438.0903; Found 438.0902. 
(RS,1S)-7-Bromo-1-(2-bromobenzyl)-N-(tert-butanesulfinyl)-1,2,3,4-tetrahydronaphthalen-1-
amine [(RS)-6h]: The representative procedure was followed by using imine (RS)-4h (481.0 mg, 
1.46 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (RS)-6h (370.0 
mg, 0.74 mmol, 51%) as a white solid; mp 130–132 ºC (hexane/CH2Cl2); [α]D20 = –59.5 (c = 0.38, 
CH2Cl2); Rf = 0.30 (hexane/EtOAc, 3:1); IR ν (neat) 2947, 1474, 1270, 1037, 912, 737, 707 cm–1; 
δH 7.59 (d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 7.28–7.20 (m, 1H), 7.15 (d, J = 7.8 Hz, 1H), 7.08–6.96 (m, 
1H), 3.64 (s, 1H), 3.40 (d, J = 13.9 Hz, 1H), 3.24 (d, J = 13.9 Hz, 1H), 2.62–2.92 (m, 2H), 2.47–
2.32 (m, 1H), 2.31–2.14 (m, 1H), 2.02 (d, J = 9.7 Hz, 2H), 1.20 (s, 9H); δC 141.1 (C), 137.6 (C), 
135.7 (C), 133.2 (CH), 132.2 (CH), 130.9 (CH), 130.2 (CH), 129.0 (CH), 127.2 (CH), 126.6 (CH), 
119.0 (C), 61.6 (C), 57.2 (C), 48.0 (CH2), 36.8 (CH2), 29.6 (CH2), 23.0 (CH3), 20.4 (CH2); LRMS 
(EI) m/z 381 (M+–t-BuSONH2, 50%), 380 (20), 379 (100), 377 (52), 197 (35), 195 (36), 171 (82), 
169 (86), 57 (39); HRMS (ESI-TOF) m/z: (M+H)+ Calcd for C21H26Br2NOS 498.0102; Found 
498.0101. 
(RS,4R)-4-(2-Bromobenzyl)-N-(tert-butanesufinyl)chroman-4-amine [(RS)-6i]: The 
representative procedure was followed by using imine (RS)-4i (340.0 mg, 1.35 mmol). Purification 
by column chromatography (hexane/AcOEt, 2:1) yielded (RS)-6i (522.8 mg, 1.24 mmol, 92%) as a 
yellow solid; mp 52–54 ºC (hexane/CH2Cl2); [α]D20  = –17.8 (c = 0.60, CH2Cl2); Rf = 0.26 
(hexane/EtOAc, 1:1); IR ν (neat) 2952, 1488, 1459, 1216, 1061, 1032, 761, 742 cm–1; δH 7.57 (dd, J 
= 7.9, 1.4 Hz, 1H), 7.23–7.03 (m, 5H), 7.00–6.78 (m, 2H), 4.46–4.21 (m, 2H), 3.69 (s, 1H), 3.59 (d, 
J = 13.9 Hz, 1H), 3.36 (d, J = 13.9 Hz, 1H), 2.57 (ddd, J = 14.5, 8.3, 3.6 Hz, 1H), 2.41–2.24 (m, 
1H), 1.20 (s, 9H); δC 156.0 (C), 135.7 (C), 133.5 (CH), 132.8 (CH), 129.3 (CH), 129.0 (CH), 128.9 
(CH), 127.3 (CH), 126.7 (C), 124.4 (C), 120.4 (CH), 117.7 (CH), 63.4 (CH2), 57.6 (C), 56.9 (C), 
48.2 (CH2), 35.6 (CH2), 23.0 (CH3); LRMS (EI) m/z 304 (M+–t-BuSONH2, 17%), 303 (97), 302 
(19), 301 (100), 196 (33), 171 (16), 169 (17), 57 (21); HRMS (ESI-TOF) m/z: (M+H)+ Calcd for 
C20H25BrNO2S 422.0789; Found 422.0781. 
(RS,4R)-4-(2-Bromobenzyl)-N-(tert-butanesufinyl)thiochroman-4-amine [(RS)-6j]: The 
representative procedure was followed by using imine (RS)-4j (490.0 mg, 1.83 mmol). Purification 
by column chromatography (hexane/AcOEt, 2:1) yielded (RS)-6j (447.8 mg, 1.02 mmol, 56%) as a 
colourless oil; [α]D20 = –44.2 (c = 0.36, CH2Cl2); Rf = 0.30 (hexane/EtOAc, 3:1); IR ν (neat) 3049, 
1474, 1430, 1256, 1042, 732, 712 cm–1; δH 7.58–7.54 (m, 1H), 7.21–7.09 (m, 5H), 6.95 (d, J = 8.1 
Hz, 1H), 6.82 (dd, J = 7.4, 2.0 Hz, 1H), 3.79 (s, 1H), 3.50 (d, J = 14.0 Hz, 1H), 3.32 (d, J = 14.0 Hz, 
1H), 3.29–3.11 (m, 2H), 2.77 (t, J = 14.5 Hz, 1H), 2.59–2.51 (m, 1H), 1.20 (s, 9H); δC 135.3 (C), 
135.1 (C), 134.7 (C), 133.1 (CH), 133.0 (CH), 129.8 (CH), 128.8 (CH), 128.5 (CH), 127.6 (CH), 
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127.1 (CH), 126.5 (C), 123.5 (CH), 60.44 (C), 57.23 (C), 46.95 (CH2), 37.24 (CH2), 23.50 (CH2), 
23.05 (CH3); LRMS (EI) m/z 320 (M+–t-BuSONH2, 18%), 319 (99), 318 (19), 317 (100), 238 (26), 
212 (27), 135 (63), 57 (27); HRMS (ESI-TOF) m/z: (M+H)+ Calcd for C20H25BrNOS2 438.0561; 
Found 438.0563. 
(SS,1R)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-1,2,3,4-tetrahydronaphthalen-1-amine 
[(SS)-6a]: The representative procedure was followed by using imine (SS)-4a (338.0 mg, 1.35 
mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (SS)-6a (396.0 mg, 
0.94 mmol, 70%). Physical and spectroscopic data were found to be same than for (RS)-6a. [α]D20 = 
+53.1 (c = 0.43, CH2Cl2). 
(SS,1R)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-
amine [(SS)-6c]: The representative procedure was followed by using imine (SS)-4c (331.0 mg, 1.18 
mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (SS)-6c (243.7 mg, 
0.54 mmol, 46%). Physical and spectroscopic data were found to be same than for (RS)-6c. [α]D20 = 
+29.8 (c = 0.64, CH2Cl2). 
(SS,1R)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-
amine [(SS)-6d]: The representative procedure was followed by using imine (SS)-4d (254.0 mg, 
0.91 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (SS)-6d (143.0 
mg, 0.32 mmol, 35%). Physical and spectroscopic data were found to be same than for (RS)-6d. 
[α]D20 = +39.2 (c = 0.21, CH2Cl2). 
(SS,1R)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-7-methoxy-1,2,3,4-tetrahydronaphthalen-1-
amine [(SS)-6e]: The representative procedure was followed by using imine (SS)-4e (278.0 mg, 0.99 
mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (SS)-6e (231.1 mg, 
0.51 mmol, 52%) Physical and spectroscopic data were found to be same than for (RS)-6e. [α]D20 = 
+49.6 (c = 0.42, CH2Cl2). 
(SS,1R)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-6,7-dimethoxy-1,2,3,4-
tetrahydronaphthalen-1-amine [(SS)-6f]: The representative procedure was followed by using 
imine (SS)-4f (160.0 mg, 0.51 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) 
yielded (SS)-6f (105.0 mg, 0.22 mmol, 43%). Physical and spectroscopic data were found to be 
same than for (RS)-6f. [α]D20 = +34.3 (c = 0.36, CH2Cl2). 
(SS,1R)-1-(2-Bromobenzyl)-N-(tert-butanesulfinyl)-7-fluoro-1,2,3,4-tetrahydronaphthalen-1-
amine [(SS)-6g]: The representative procedure was followed by using imine (SS)-4g (444.0 mg, 
1.66 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (SS)-6g (544.0 
mg, 1.24 mmol, 75%). Physical and spectroscopic data were found to be same than for (RS)-6g. 
[α]D20 = +50.6 (c = 0.64, CH2Cl2). 
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(SS,1R)-7-Bromo-1-(2-bromobenzyl)-N-(tert-butanesulfinyl)-1,2,3,4-tetrahydronaphthalen-1-
amine [(SS)-6h]: The representative procedure was followed by using imine (SS)-4h (317.0 mg, 
0.96 mmol). Purification by column chromatography (hexane/AcOEt, 2:1) yielded (SS)-6h (282.2 
mg, 0.57 mmol, 60%). Physical and spectroscopic data were found to be same than for (RS)-6h. 
[α]D20 = +47.7 (c = 0.54, CH2Cl2). 
(SS,4S)-4-(2-Bromobenzyl)-N-(tert-butanesufinyl)chroman-4-amine [(SS)-6i]: The representative 
procedure was followed by using imine (SS)-4i (400.0 mg, 1.60 mmol). Purification by column 
chromatography (hexane/AcOEt, 2:1) yielded (SS)-6i (572.5 mg, 1.36 mmol, 85%). Physical and 
spectroscopic data were found to be same than for (RS)-6i. [α]D20 = +21.5 (c = 0.90, CH2Cl2). 
(SS,4S)-4-(2-Bromobenzyl)-N-(tert-butanesufinyl)thiochroman-4-amine [(SS)-6j]: The 
representative procedure was followed by using imine (SS)-4j (490.0 mg, 1.83 mmol). Purification 
by column chromatography (hexane/AcOEt, 2:1) yielded (SS)-6j (543.8 mg, 1.24 mmol, 68%). 
Physical and spectroscopic data were found to be same than for (RS)-6j. [α]D20 = +40.3 (c = 0.32, 
CH2Cl2). 
 
General Procedure for the Synthesis of Spiro compounds 8 from Sulfinamides 6: To a solution 
of the corresponding sulfinamide 6 (0.5 mmol) in MeOH (5.0 mL) was added a 2M solution of HCl 
in Et2O (2.5 mL, 5.0 mmol). The reaction mixture was stirred at 23 ºC for 2 h. Removal of the tert-
butanesulfinyl group with concomitant formation of the free amine hydrochloride was followed by 
TLC. Solvents were evaporated (15 Torr) and the resulting residue was treated with CH2Cl2 (20 
mL) and saturated aqueous solution of NaHCO3 (15 mL). The organic layer was dried over with 
anhydrous MgSO4, and the solvent evaporated (15 Torr). The resulting free amine 7 was transferred 
to a high pressure flask, and  triphenylphosphine (19.7 mg, 0.075 mmol), Pd(OAc)2 (5.6 mg, 0.025 
mmol), Cs2CO3 (325 mg, 1.0 mmol) and toluene (5 mL) were successively added. The reaction 
mixture was stirred at 110 ºC for 20 h. After that it was cooled down to room temperature and 
hydrolyzed, first with 3M HCl (3.0 mmol, 1 mL), then with 2M NaOH (8.0 mmol, 4 mL), and 
extracted with EtOAc (4 × 15 mL). The organic layers were successively washed with brine (15 
mL) and then dried with anhydrous MgSO4 , and concentrate under vacuum (15 Torr). The residue 
was purified by column chromatography (silica gel, hexane/EtOAc) to yield products 8. Yields are 
given on Table 2, physical and spectroscopic data follow. 
(S)-3',4'-Dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(S)-8a]: The representative procedure 
was followed by using (RS)-6a (86.0 mg, 0.20 mmol). Purification by column chromatography 
(hexane/AcOEt, 20:1) yielded (S)-8a (31.0 mg, 0.132 mmol, 66%) as a yellow solid; mp 75–77 ºC 
(hexane/CH2Cl2); [α]D20 = –15.0 (c = 0.45, CH2Cl2); Rf = 0.50 (hexane/EtOAc, 9:1); IR ν (neat) 
3375, 2933, 2851, 1606, 1484, 1433, 1258, 1104, 1024, 767, 745 cm–1; δH 7.62–7.49 (m, 1H), 7.09 
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(dt, J = 27.6, 7.5 Hz, 5H), 6.73 (t, J = 7.4 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 3.28 (d, J = 16.1 Hz, 
1H), 3.22 (d, J = 16.1 Hz, 1H), 2.89–2.74 (m, 2H), 2.16–2.06 (m, 1H), 1.90 (t, J = 7.4 Hz, 3H); δC 
149.8 (C), 143.3 (C), 136.3 (C), 128.8 (CH), 127,6 (CH) 127.4 (C), 126.9 (CH), 126.7 (CH) 126.5 
(CH), 124.8 (CH), 118.8 (CH), 109.0 (CH), 64.9 (C), 46.4 (CH2), 37.7 (CH2), 29.7 (CH2), 20.3 
(CH2); LRMS (EI) m/z 235 (M+, 100%), 234 (34), 220 (43), 207 (34), 206 (54), 106 (51); HRMS 
(EI) m/z: M+ Calcd for C17H17N 235.1361; Found 235.1362. 
(2S,4’R*)-4’-Methyl-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(S)-8b]: The 
representative procedure was followed by using (RS)-6b (113.0 mg, 0.26 mmol). Purification by 
column chromatography (hexane/AcOEt, 20:1) yielded (S)-8b (20.7 mg, 0.083 mmol, 32%) as a 
mixture of diastereoisomers (1:1); yellow solid; mp 60–63 ºC (hexane/CH2Cl2); Rf = 0.51 
(hexane/EtOAc, 9:1); IR ν (neat) 3392, 2924, 1725, 1607, 1484, 1463, 1261, 1018, 743 cm–1; δH 
7.59 (t, J = 5.1 Hz, 2H), 7.34–6.99 (m, 12H), 6.86–6.47 (m, 2H), 3.30 (d, J = 3.5 Hz, 2H), 3.27 (s, 
2H), 2.99 (dd, J = 13.6, 7.7 Hz, 2H), 2.32–2.05 (m, 6H), 1.97–1.84 (m, 1H), 1.78–1.58 (m, 3H), 
1.38 (d, J = 1.9 Hz, 3H), 1.36 (d, J = 2.1 Hz, 3H); δC 141.4 (C), 141.1 (C), 128.3 (CH), 127.7 (CH), 
127.6 (CH), 127.2 (CH), 126.7 (CH), 126.5 (CH), 126.5 (CH), 124.8 (CH), 118.8 (CH), 109.1 
(CH), 65.1 (C), 60.4 (C), 46.3 (CH2), 36.0 (CH2), 33.7 (CH2), 32.8 (CH3), 32.3 (CH3), 29.7 (CH2), 
29.0 (CH2) 28.2 (CH2), 23.2 (CH3), 22.4 (CH3); LRMS (EI) m/z 249 (M+, 100%), 248 (30), 234 
(74), 106 (53); HRMS (EI) m/z: M+ Calcd for C18H19N 249.1517; Found 249.1511. 
(S)-5’-Methoxy-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(S)-8c]: The representative 
procedure was followed by using (RS)-6c (143.0 mg, 0.32 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (S)-8c (50.8 mg, 0.192 mmol, 60%) as a yellow 
solid; mp 104–107 ºC (hexane/CH2Cl2); [α]D20 = –1.3 (c = 0.76, CH2Cl2); Rf = 0.48 (hexane/EtOAc, 
9:1); IR ν (neat) 3392, 2918, 2854, 1604, 1582, 1458, 1435, 1247, 1031, 780, 742 cm–1; δH 7.20–
7.08 (m, 4H), 6.81–6.65 (m, 3H), 3.85 (s, 3H), 3.34–3.18 (m, 2H), 2.74–2.69 (m, 2H), 2.06 (d, J = 
12.1 Hz, 1H), 1.95–1.83 (m, 3H); δC 158.0 (C), 152.3 (C), 146.2 (C), 128.6 (C) 128.4 (CH), 127.4 
(CH), 126.2 (C), 125.4 (CH), 119.5 (CH), 119.1 (CH), 109.6 (CH), 108.7 (CH), 65.6 (C), 55.8 
(CH3), 47.4 (CH2), 38.1 (CH2), 24.2 (CH2), 20.6 (CH2); LRMS (EI) m/z 265 (M+, 100%), 264 (36), 
250 (42), 106 (56); HRMS (EI) m/z: M+ Calcd for C18H19NO 265.1467; Found 265.1462.  
(S)-6’-Methoxy-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(S)-8d]: The representative 
procedure was followed by using imine (RS)-6d (30.4 mg, 0.067 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (S)-8d (8.5 mg, 0.032 mmol, 48%) as a yellow 
solid; mp 96–98 ºC (hexane/CH2Cl2); [α]D20 = –50.1 (c =  0.71, CH2Cl2); Rf = 0.30 (hexane/EtOAc, 
9:1); IR ν (neat) 3397, 2940, 2924, 1604, 1482, 1464, 1242, 1226, 1034, 1021, 837, 744 cm–1; δH 
7.45 (d, J = 8.7 Hz, 1H), 7.18–7.07 (m, 2H), 6.94–6.67 (m, 3H), 6.61 (s, 1H), 3.77 (s, 3H), 3.31 (d, 
J = 24.4 Hz, 2H), 2.83 (d, J = 20.1 Hz, 2H), 2.12–1.84 (m, 4H); δC 159.7 (C), 152.2 (C), 138.7 (C), 
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137.3 (C), 128.8 (CH), 128.7 (C), 128.4 (CH), 125.4 (CH), 119.1 (CH), 113.6 (CH), 113.6 (CH), 
109.7 (CH), 65.5 (C), 55.5 (CH3), 47.5 (CH2), 38.8 (CH2), 31.1 (CH2), 21.5 (CH2); LRMS (EI) m/z 
265 (M+, 100%), 264 (40), 250 (48), 237 (29); HRMS (EI) m/z: M+ Calcd for C18H19NO 265.1467; 
Found 265.1481. 
(S)-7’-Methoxy-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(S)-8e]: The representative 
procedure was followed by using imine (RS)-6e (195.0 mg, 0.42 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (S)-8e (69.0 mg, 0.26 mmol, 62%) as a yellow solid; 
mp 100–103 ºC (hexane/CH2Cl2); [α]D20 = –18.7 (c = 0.83, CH2Cl2); Rf = 0.40 (hexane/EtOAc, 9:1); 
IR ν (neat) 3392, 2918, 2854, 1604, 1582, 1487, 1458, 1435, 1247, 1031, 780, 742 cm–1; δH 7.18 (d, 
J = 2.7 Hz, 1H), 7.14–6.98 (m, 3H), 6.80–6.72 (m, 2H), 6.67 (d, J = 4.8 Hz, 1H), 3.73 (s, 3H), 3.26 
(s, 2H), 2.79 (d, J = 6.3 Hz, 2H), 2.19–2.08 (m, 1H), 1.94–1.88 (m, 3H) ; δC 158.2 (C), 150.0 (C), 
144.5 (C), 129.8 (CH), 128.7 (C), 127.7 (CH), 127.4 (CH), 124.9 (CH), 118.8 (CH), 113.8 (CH), 
111.2 (CH), 109.1 (CH), 65.4 (C), 55.4 (CH3), 46.4 (CH2), 37.4 (CH2), 20.5 (CH2); LRMS (EI) m/z 
265 (M+, 100%), 264 (29), 250 (37), 237 (38), 236 (44), 192 (19), 159 (26), 144 (22), 115 (24), 106 
(52); HRMS (EI) m/z: M+ Calcd for C18H19NO 265.1467; Found 265.1452. 
(S)-6’,7’-Dimethoxy-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(S)-8f]: The 
representative procedure was followed by using imine (RS)-6f (40.9 mg, 0.085 mmol). Purification 
by column chromatography (hexane/AcOEt, 20:1) yielded (S)-8f (10.1 mg, 0.034 mmol, 40%) as a 
yellow solid; mp 120–121 ºC (hexane/CH2Cl2); [α]D20 = –23.7 (c =  0.44, CH2Cl2); Rf = 0.12 
(hexane/EtOAc, 9:1); IR ν (neat) 3060, 2928, 2852, 1608, 1509, 1462, 1253, 1217, 1125, 746 cm–1; 
δH 7.13 (s, 1H), 7.12–7.03 (m, 2H), 6.88–6.64 (m, 2H), 6.55 (s, 1H), 3.86 (s, 3H), 3.74 (s, 3H), 3.23 
(d, J = 4.3 Hz, 2H), 2.76 (d, J = 5.6 Hz, 2H), 2.13 (d, J = 9.8 Hz, 1H), 1.90 (d, J = 5.1 Hz, 3H); δC 
152.3 (C), 149.3 (C), 148.7 (C), 137.1 (C), 130.3 (C), 128.7 (C), 128.5 (CH), 125.5 (CH), 119.1 
(CH), 112.6 (CH), 111.1 (CH), 109.7 (CH), 65.9 (C), 56.3 (CH3), 56.2 (CH3), 47.3 (CH2), 38.2 
(CH2), 30.3 (CH2), 21.6 (CH2); LRMS (EI) m/z 295 (M+, 100%), 280 (28), 264 (46), 189 (38), 180 
(28), 108 (29), 106 (32); HRMS (EI) m/z: M+ Calcd for C19H21NO2 295.1572; Found 295.1571. 
(S)-7’-Fluoro-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(S)-8g]: The representative 
procedure was followed by using imine (RS)-6g (140.0 mg, 0.32 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (S)-8g (51.8 mg, 0.205 mmol, 64%) as a yellow 
solid; mp 65–68 ºC (hexane/CH2Cl2); [α]D20 = –21.9 (c =  0.96, CH2Cl2); Rf = 0.44 (hexane/EtOAc, 
9:1); IR ν (neat) 3364, 2925, 2843, 1718, 1609, 1484, 1466, 1261, 1220, 1024, 875, 743 cm–1; δH 
7.31–7.22 (m, 1H), 7.04 (dd, J = 16.9, 6.7 Hz, 3H), 6.81 (d, J = 36.9 Hz, 2H), 6.69 (s, 1H), 3.23 (s, 
2H), 2.79 (d, J = 11.7 Hz, 2H), 2.12 (d, J = 19.9 Hz, 1H), 1.92–1.83 (m, 3H); δC 161.2 (d, J = 242.1 
Hz, C), 150.7 (C), 146.0 (d, J = 6.3 Hz, C), 137.1 (C), 129.9 (d, J = 7.7 Hz, CH), 127.2 (CH), 126.6 
(C), 124.1 (CH), 117.8 (CH), 113.3 (d, J = 21.8 Hz, CH), 112.2 (d, J = 21.7 Hz, CH), 108.2 (CH), 
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64.5 (C), 46.1 (CH2), 36.4 (CH2), 28.5 (CH2), 19.9 (CH2); LRMS (EI) m/z 253 (M+, 100%), 252 
(28), 238 (37), 225 (30), 224 (44), 106 (39); HRMS (EI) m/z: M+ Calcd for C17H16 FN 253.1267; 
Found 253.1257. 
(S)-7’-Bromo-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(S)-8h]: The representative 
procedure was followed by using imine (RS)-6h (100.0 mg, 0.20 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (S)-8h (18.8 mg, 0.060 mmol, 30%) as a yellow 
solid; mp 131–134 ºC (hexane/CH2Cl2); [α]D20 = –30.2 (c =  0.98, CH2Cl2); Rf = 0.47 
(hexane/EtOAc, 9:1); IR ν (neat) 3368, 2928, 2861, 1719, 1606, 1482, 1464, 1262, 1020, 815, 744, 
708 cm–1; δH 7.78 (s, 1H), 7.28 (d, J = 8.2 Hz, 2H), 7.10 (d, J = 7.6 Hz, 2H), 6.97 (d, J = 8.2 Hz, 
1H), 6.82 (d, J = 7.3 Hz, 1H), 3.25 (s, 2H), 2.79 (t, J = 6.2 Hz, 2H), 2.15 (d, J = 9.4 Hz, 1H), 1.94–
1.87 (m, 3H); δC 152.0 (C), 147.7 (C), 136.6 (C), 131.6 (CH), 130.7 (CH), 130.6 (CH), 128.6 (CH), 
127.8 (C), 125.5 (CH), 120.5 (C), 119.2 (CH), 109.6 (CH), 65.7 (C), 47.5 (CH2), 37.7 (CH2), 30.0 
(CH2), 21.0 (CH2); LRMS (EI) m/z 315 (M+, 96%), 313 (100), 300 (29), 298 (32), 204 (39), 106 
(61); HRMS (EI) m/z: M+ Calcd for C17H16BrN 313.0466; Found 313.0455. 
(R)-Spiro[chromane-4,2'-indoline] [(R)-8i]: The representative procedure was followed by using 
imine (RS)-6i (224.0 mg, 0.53 mmol). Purification by column chromatography (hexane/AcOEt, 
20:1) yielded (R)-8i (71.6 mg, 0.30 mmol, 57%) as a yellow solid; mp 110–112 ºC 
(hexane/CH2Cl2); [α]D20 = –30.1 (c =  0.91, CH2Cl2); Rf = 0.30 (hexane/EtOAc, 9:1); IR ν (neat) 
3370, 3046, 1606, 1482,1448, 1248, 1226, 1052, 1033, 761, 746 cm–1; δH 7.49 (d, J = 7.8 Hz, 1H), 
7.23–7.10 (m, 3H), 6.87 (m, 3H), 6.75 (d, J = 7.8 Hz, 1H), 4.33 (d, J = 28.0 Hz, 2H), 3.52–3.42 (m, 
1H), 3.23 (d, J = 16.1 Hz, 1H), 2.24 (d, J = 10.7 Hz, 2H); δC 153.8 (C), 150.5 (C), 129.3 (C), 128.0 
(CH), 127.2 (CH), 126.7 (C), 126.5 (CH), 124.1 (CH), 120.2 (CH), 118.0 (CH), 116.2 (CH), 108.5 
(CH), 63.5 (CH2), 60.6 (C), 45.6 (CH2), 35.7 (CH2); LRMS (EI) m/z 237 (M+, 100%), 238 (18), 236 
(58), 210 (47), 180 (49), 131 (32), 89 (32), 77 (32); HRMS (EI) m/z: M+ Calcd for C16H15NO 
237.1154; Found 237.1137. 
(R)-Spiro[indoline-2,4'-thiochromane] [(R)-8j]: The representative procedure was followed by 
using imine (RS)-6j (258.0 mg, 0.61 mmol). Purification by column chromatography 
(hexane/AcOEt, 20:1) yielded (R)-8j (103.8 mg, 0.41 mmol, 67%) as a yellow solid; mp 103–105 
ºC (hexane/CH2Cl2); [α]D20 = –44.3 (c =  0.92, CH2Cl2); Rf = 0.40 (hexane/EtOAc, 9:1); IR ν (neat) 
3370, 2944, 1066, 1482, 1448, 1259, 1248, 1052, 761 cm–1; δH 7.54 (d, J = 8.2 Hz, 1H), 7.16–6.94 
(m, 5H), 6.86–6.65 (m, 2H), 3.34–3.27 (m, 4H), 2.46–2.19 (m, 2H); δC 150.6 (C), 140.4 (C), 132.3 
(C), 127.2 (CH), 126.7 (CH), 126.6 (CH), 126.4 (CH), 125.8 (CH), 124.1 (CH), 123.8 (CH), 117.8 
(CH), 108.1 (CH), 63.4 (C), 44.7 (CH2), 35.3 (CH2), 22.8 (CH2); LRMS (EI) m/z 253 (M+, 100%), 
226 (52), 223 (38), 147 (34); HRMS (EI) m/z: M+ Calcd for C16H15NS 253.0925; Found 253.0919. 
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(R)-3',4'-Dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(R)-8a]: The representative procedure 
was followed by using imine (SS)-6a (178.0 mg, 0.42 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (R)-8a (55.3 mg, 0.235 mmol, 56%).  Physical and 
spectroscopic data were found to be same than for (S)-8a. [α]D20 = +16.5 (c = 0.53, CH2Cl2). 
(R)-5’-Methoxy-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(R)-8c]: The representative 
procedure was followed by using imine (SS)-6c (80.0 mg, 0.17 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (R)-8c (25.7 mg, 0.097 mmol, 57%). Physical and 
spectroscopic data were found to be same than for (S)-8c. [α]D20 = +2.5 (c = 0.83, CH2Cl2). 
(R)-6’-Methoxy-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(R)-8d]: The representative 
procedure was followed by using imine (SS)-6d (135.0 mg, 0.30 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (R)-8d (46.2 mg, 0.174 mmol, 58%). Physical and 
spectroscopic data were found to be same than for (S)-8d. [α]D20 = +47.7 (c = 0.54, CH2Cl2). 
(R)-7’-Methoxy-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(R)-8e]: The representative 
procedure was followed by using imine (SS)-6e (160.0 mg, 0.35 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (R)-8e (60.3 mg, 0.227 mmol, 65%). Physical and 
spectroscopic data were found to be same than for (S)-8e. [α]D20 = +22.3 (c = 0.93, CH2Cl2). 
(R)-6’,7’-Dimethoxy-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(R)-8f]: The 
representative procedure was followed by using imine (SS)-6f (98.3 mg, 0.20 mmol). Purification by 
column chromatography (hexane/AcOEt, 20:1) yielded (R)-8f (29.6 mg, 0.10 mmol, 49%). Physical 
and spectroscopic data were found to be same than for (S)-8f. [α]D20 = +20.8 (c = 0.66, CH2Cl2). 
(R)-7’-Fluoro-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(R)-8g]: The representative 
procedure was followed by using imine (SS)-6g (289.0 mg, 0.65 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (R)-8g (88.8 mg, 0.351 mmol, 54%). Physical and 
spectroscopic data were found to be same than for (S)-8g. [α]D20 = +31.0 (c = 0.94, CH2Cl2). 
(R)-7’-Bromo-3',4'-dihydro-2'H-spiro[indoline-2,1'-naphthalene] [(R)-8h]: The representative 
procedure was followed by using imine (SS)-6h (250.0 mg, 0.50 mmol). Purification by column 
chromatography (hexane/AcOEt, 20:1) yielded (R)-8h (34.4 mg, 0.11 mmol, 22%). Physical and 
spectroscopic data were found to be same than for (S)-8h. [α]D20 = +64.8 (c = 0.92, CH2Cl2). 
(S)-Spiro[chromane-4,2'-indoline] [(S)-8i]: The representative procedure was followed by using 
imine (SS)-6i (158.0 mg, 0.37 mmol). Purification by column chromatography (hexane/AcOEt, 
20:1) yielded (S)-8i (48.2 mg, 0.203 mmol, 55%). Physical and spectroscopic data were found to be 
same than for (R)-8i. [α]D20 = +31.2 (c = 0.93, CH2Cl2). 
(S)-Spiro[indoline-2,4'-thiochromane] [(S)-8j]: The representative procedure was followed by 
using imine (SS)-6j (140.0 mg, 0.32 mmol). Purification by column chromatography 
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(hexane/AcOEt, 20:1) yielded (S)-8j (58.3 mg, 0.23 mmol, 72%). Physical and spectroscopic data 
were found to be same than for (R)-8j. [α]D20 = +49.4 (c = 0.98, CH2Cl2). 
 
Cell Culture Methods 
The chronic myeloid leukemia cell lines K562 and FEPS were cultured in RPMI-1640 medium 
(Sigma-Aldrich, St Louis, MO, USA) supplemented with 25 mM HEPES adjusted to pH 7.4 with 
NaOH, 60 mg.L-1 penicillin and 100 mg.L-1 streptomycin (all obtained from Sigma-Aldrich). Dr. 
Vivian M. Rumjanek kindly donated FEPS cells. Briefly, K562 cells were exposed to increasing 
concentrations of the chemotherapeutic drug daunorubicin hydrochloride (DNR) (Sigma-Aldrich), 
as described before32. FEPS (K562/DNR) cells were cultured in the presence of 500 nM DNR in 
order to maintain the MDR phenotype. For subcultures, cells were harvested every three days 
followed by washing with cold phosphate-buffered saline, and maintained at 37 ºC in 5% CO2. All 
media was supplemented with 10% fetal bovine serum (FBS) (Thermo Fischer Scientific, Waltham, 
MA, USA) inactivated at 56 °C for 1 h prior to use. 
 
In vitro cell viability 
Cell viability was determined with the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT; Sigma-Aldrich). Prior to the experiments, the MDR FEPS cells were 
cultured free of DNR to avoid additive effect. Briefly, 104 mL-1 leukemia cells were treated with 
compounds at a range of concentrations and incubated for 72 h at 37 ºC. Negative controls were 
prepared with DMSO 0.1% (Vetec Química Fina, Duque de Caxias, RJ, Brasil), and positive ones 
with VCR or DNR. Then, media was replaced with fresh RPMI supplemented with 10% FBS, 20 
μL MTT (5 mg.mL-1) was added to each well and plates were kept at 37 °C in 5% CO2 for 3 h. 
Plates were then centrifuged, and 200 μL DMSO was added to dissolve the formazan crystals 
formed after MTT reduction. Absorbance was measured on a Beckman Coulter AD340S 
spectrophotometer microplate reader (Beckman Coulter, Brea, CA, USA) at 570 nm. The 
percentage of viable cells was determined in comparison to the control wells. The half-maximal 
inhibitory concentrations (IC50) were calculated by non-linear regression using the GraphPad Prism 
version 7.0 program (GraphPad Software, San Diego, CA, USA). The relative resistance (RR) was 
calculated using the formula (RR) = (IC50 resistant cell line, FEPS) ⁄ (IC50 parental cell line, 
K562). When IC50 exceeded the maximal tested concentration it was expressed as being higher than 
this concentration (e.g. >200), and this value, 200, was used for calculating the RR (e.g. RR of (R)-
8i: IC50 FEPS / IC50 K562 = 154.83/200 = 0.77). If RR ≤ 0.5, the compound exerted collateral 
sensitivity44, and cells were considered resistant when RR ≥ 2.0. 
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Supporting Information. Copies of 1H, 13C NMR and DEPT spectra for all the reported 
compounds, 19F NMR for compound RS)-6g, X-ray structure of compound (RS)-6h (Figure S1), as 
well as computational methods, transitions structures, energy values, energy profiles, NCI 
calculations and cartesian coordinates. 
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